Natural Approach to Improved Health of Retinas, Maculas and Eye Capillaries
Licensed and sold for eye and vascular health in France since 1950, the retinal and vascular protective activities of Flavay® have been established by many significant studies.
Taking Flavay® resulted in improvement in 147-out-of-147 (100%) cases of exudations linked to ischemia (inadequate blood supply) linked to a diabetic, ateriosclerotic, inflammatory, degenerative and myopic nature. (71)
Taking Flavay® resulted in overall improvement in 21-out-of-26 (81%) of subjects with retinopathy and capillary fragility, microaneurysms, exudates and hemorrhages, taking of the subjects. The condition of the ocular fundas improved in 15 subjects and capillary fragility improved in 11 subjects. (250)
In various clinical trials, all persons given Flavay® showed significant improvement with various types of retinal diseases, including macular degeneration, diabetic retinopathy, retinitis pigmentosa, and hemorrhagic and hypertensive retinopathy. (69-72)
Microbleedings in retinal tissue are reduced and visual acuity can improve when taking Flavay® (249,250)
Flavay® has been sold world-wide for vascular and eye health since 1950 and extensively tested in humans. Research shows several important ways in which Flavay® may protect the vascular health of your eyes:
- Flavay® supports overall circulatory function,
- Flavay® reinforces collagen structures of the retina (which is 80% collagen),
- Flavay® protects your eyes from oxidative damage,
- Flavay® enhances your eye’s ability to visually adapt to glare and different light environments, and
- Flavay® protects the health of your eyes and retinas.
Human Clinical Trials
A review of 26 case studies reveals Flavay® significantly improved vascular lesions, microaneurysms, and exudates associated with diabetic retinopathy. (71)
The effects of Flavay® (100 mg per day) were measured on 147 subjects with retinopathy. Flavay® improved all cases of exudations linked to ischemia (inadequate blood supply) linked to a diabetic, ateriosclerotic, inflammatory, degenerative and myopic nature. (69)
The effects of Flavay® (150 mg per day) were measured on 30 retinopathy subjects who suffered from microaneurysms, hemorrhages, exudations and neovascularization after capillary hypoxia. Retinal infectional lesions were stabilized in 80% of subjects taking Flavay®. (72)
An open study measured the effects of Flavay® on 26 subjects with retinopathy and capillary fragility, microaneurysms, exudates and hemorrhages. Capillary fragility (measured with Parrot’s angiosterrometer) improved in 11 subjects, condition of the ocular fundus improved in 15 subjects, and overall improvement in 21 subjects was reported. (250)
Flavay® Improves Circulation
Your retinas require a constant supply of blood for nutrients and oxygen.
Flavay® improves circulation, including micro-circulation, nutrient delivery and strengthens collagen in vascular walls. (1-3,44-48)
The health of your eyes depends to a great extent on the integrity of the fine vessels that supply blood to the area. Research shows various ways Flavay® can improve visual performance. Flavay® helps to prevent and relieve vascular fragility by strengthening vessels and reducing the risk of a rupture or hemorrhage. (23,35,36,77-79,87,146,267,268)
- Flavay® strengthens collagen in vascular walls and capillaries (the smallest vessels), making the vessels stronger and more elastic.
- Flavay® alters the membrane receptor conformation of vascular walls, reducing the damaging effects of the destructive enzymes elastase, collagenase and hyaluronidase, by preventing them from attaching to and degrading vascular walls.
- Flavay® further prevents destruction of vascular walls by preventing the attachment to membranes of histamine and hyaluronidase, both of which can decrease the strength of vessel walls. (23,35,36,77-79,87,146,267,268)
Flavay® is also shown to improve the endothelial function of micro-vessels which supports improved blood micro-circulation in the eyes. (53,264,274)
Flavay® Protects the Smallest Blood Vessels in Your Eyes and Improves Capillary Fragility
The vascular protective activity of Flavay® is well documented. Flavay® is shown to increase capillary resistance, decrease capillary permeability, and increase rate of lymph flow. (47,48,82,205)
In the eyes, Flavay® is shown to reduce pressure in ophthalmic membranes by preventing abnormal leakage of fluids into the orbital cavity and tissues and thereby slow down progression of retinopathies. Flavay® seals leaky capillaries as it causes strong protein binding which prevents outflow of blood or liquid from leaky capillaries. The number of microbleedings in retinal tissue is reduced and visual acuity can improve. (249,250)
Human clinical trials show very favorable results using Flavay®. A French trial of persons with serious venous problems found 75 out of 78 (96%) of the subjects experienced improvement in circulation. (44)
In France, Flavay® is used to improve a variety of peripheral circulatory problems characterized by capillary fragility and impaired venous drainage. (2,44-48,270)
A French trial of 78 subjects with serious venous problems found very favorable results using Flavay®. 75 out of 78 (96%) subjects experienced improvement in circulation. (44)
A review of three small French double-blind clinical trials concluded that in subjects with chronic venous insufficiency, Flavay® was significantly more helpful than placebo in improving venous function in terms of edema, pain, paresthesias and nocturnal leg cramps. (42,230)
A much larger French study of 4,729 women reported that taking Flavay® (300 mg daily for three months) produced significant improvement in venous and lymphatic insufficiency. (59)
A double-blind, placebo-controlled study of 92 subjects with chronic venous insufficiency demonstrated improved venous function at a daily dose of 300 mg Flavay® for 28 days. 69% of those taking Flavay® reported 50% reduction in clinical parameter scores for pain, paresthesias, nocturnal cramps and edema. 75% of those taking Flavay® felt it was effective, compared to 41% of the placebo group. (48)
UV light induces oxidative stress to the front of the eye (particularly the cornea and lens), and “blue” light reaches deeper into the eye where its cumulative oxidative stress can cause damage to the retina. (320-322,326)
Due to the exposure to light and oxygen, the oxidative stress burden is higher in the eye than other tissues. Oxidative damage in responsible for macular degeneration, glaucoma, retinal degeneration and retinopathies, and cataracts. Our eyes (which are 80% collagen) rely on specialized aqueous (water) and lipid (fat) barriers for protection. But, our body's repair mechanisms become progressively less effective as we age. (323-327)
Free Radicals, Cataracts and Macular Degeneration
Oxidative damage is responsible for macular degeneration, glaucoma, retinal degeneration and retinopathies, and cataracts. (257-259,299)
Flavay® is patented as a “free-radical scavenger,” as it effectively protects cells in both the aqueous (water) and lipid (fat) phases of oxidation. (1,8-54,63,103,202)
Oxygen and light generate free radicals or precursors, and oxidative damage to lens proteins leads to increasing opacity. It's been shown, through both animal and human studies, that oxidative stress plays a critical role in macular degeneration, glaucoma, retinal degeneration and retinopathies, and cataracts. (257-259,299)
Due to the exposure to sunlight and high oxygen concentration, the oxidative stress burden is higher in the eye than other tissues, which can be further complicated by additional oxidative stressors such as smoke, smog, chemical pollution and chronic exposure to “blue light” digital-screen radiation. (323-327)
Flavay® Protects Retinal Cells From Oxidation
Oxidative stress is a major cause of cell death and the hallmark of optic neurodegenerative diseases (including retinopathy and glaucoma) is retinal ganglion cell-death. (257-259,299)
Studies show Flavay® protects oxidative stress-injured retinal ganglion cells by inhibiting apoptosis (death). (328,329)
Antioxidant vitamins A, C and E are found decreased in diabetic persons. Also, a number of studies have shown that diabetes mellitus (types 1 and 2) is accompanied by increased formation of free radicals and decreased antioxidant capacity, leading to oxidative damage of cell components. (190,191)
Our body's repair mechanisms become progressively less effective as we age. A number of epidemiologic studies have found that persons with age-related eye diseases had significantly lower levels of antioxidants, particularly vitamin C, than did persons who did not develop those eye conditions. Research shows Flavay® increases intracellular vitamin C levels and dramatically extends the lifetime of vitamin C in the human body. Also, Flavay® provides its own powerful antioxidant protection to the eyes and its tiny blood vessels, and Flavay® enhances the protective effect of vitamin E and has been found to support the activity of vitamin A in human eyes. (1,81,63,64,71,202,260)
Clinical studies conclusively demonstrated Flavay’s® ability to stabilize microcapillaries in the retinal membranes and it has therefore been licensed in France for use in diabetic retinopathy. This shows that Flavay® should be part of the daily nutritional regimen of every aging person (most especially every diabetic person).